Dr. Ellisen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
55 Fruit St
Grj 904
Boston, MA 02114Phone+1 617-724-1399Fax+1 617-726-8623- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997- Brigham and Women's HospitalResidency, Internal Medicine, 1992 - 1994
Stanford University School of MedicineClass of 1992
Certifications & Licensure
MA State Medical License 1994 - 2025
Publications & Presentations
PubMed
- Genomic spectrum of actionable alterations in serial cell free DNA (cfDNA) analysis of patients with metastatic breast cancer.Yael Bar, Jennifer C Keenan, Andrzej Niemierko, Arielle J Medford, Steven J Isakoff, Leif W Ellisen, Aditya Bardia, Neelima Vidula> ;NPJ Breast Cancer. 2024 Apr 11
- Meiotic protein SYCP2 confers resistance to DNA-damaging agents through R-loop-mediated DNA repair.Wang, Y., Gao, B., Zhang, L., Wang, X., Zhu, X., Yang, H., Zhang, F., Zhu, X., Zhou, B., Yao, S., Nagayama, A., Lee, S., Ouyang, J., Koh, S., Eisenhauer, E., Zarrella,...> ;Nature Communications. 2024 Feb 21
- Optimizing Access to Liquid Biopsy in the Present and Future Cancer Landscape.Medford, A., Ellisen, L.> ;JCO Precision Oncology. 2024 Jan 1
- Join now to see all
Press Mentions
Mechanisms of Resistance to Drug for Triple-Negative Breast Cancer IdentifiedAugust 17th, 2021- Researchers Identify Mechanisms of Resistance to Drug for Triple-Negative Breast CancerAugust 17th, 2021
- Scientists Discover How Triple-Negative Breast Cancer Can Defeat Powerful DrugsAugust 16th, 2021
- Join now to see all
Grant Support
- P63 Mechanisms And Mediators In HnsccNational Institute Of Dental &Craniofacial Research2011
- Function And Mechanism Of REDD1 Signaling To TSC1/2 And MTORC1National Cancer Institute2007–2011
- P63 Mediators As Therapeutic Targets In HnsccNational Institute Of Dental &Craniofacial Research2004–2010
- Telomerase Functions In Differentiation &TransformationNational Cancer Institute1999–2003
Hospital Affiliations
Massachusetts General HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
